Turn Therapeutics Inc. filed an 8-K to furnish an updated corporate investor presentation dated October 6, 2026. The filing discloses that the company holds approximately $10.3 million in cash as of June 30, 2026, with a runway extending into Q3 2027 and access to additional capital under existing facilities. The presentation details interim Phase 2 data for GX-03 in moderate-to-severe atopic dermatitis (AD), noting statistically significant treatment separation over vehicle controls in key efficacy endpoints such as vIGA-AD success and EASI-75 improvement. Topline results for the AD trial are expected in Q1 2027, with Phase 3 initiation planned subsequently. The company also outlined pipeline milestones for GX-03 in onychomycosis (Phase 3 ready) and hidradenitis suppurativa (Phase 2a initiation planned). Turn Therapeutics is a biotechnology company developing precision immunomodulation therapies targeting inflammatory skin diseases.
